CLINICAL_TRIALS
trial_result
· 2017-05-09
Clinical Trial Update: Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis [Phase 2]
Summary
A Phase 2 dose-ranging study of RPC4046 for eosinophilic esophagitis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celgene | Conditions: Eosinophilic Esophagitis | Phase 2 | Status: COMPLETED